Phaseline

Targets › CSFL3

CSFL3: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: the race on CSFL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterGlycosylated Recombinant Human G-CSF AVI-014
G-CSF receptor agonist
CSFL3Phase 1Secondary MyelofibrosisApr 2027

Conditions

Secondary Myelofibrosis (1)

Modalities

mixed (1)

Companies

City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.